Clinical efficacy and safety of brodalumab (KHK4827), antiinterleukin-17-receptor a monoclonal antibody, in Japanese patients with pustular psoriasis (generalized) and psoriatic erythroderma: A phase 3, open-label, long-term study (4827-004 study)
2015 ◽
Vol 72
(5)
◽
pp. AB228
Keyword(s):
Phase 3
◽